Hengenix Biotech, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2010-01-01
- Employees
- 51
- Market Cap
- -
- Website
- https://hengenix.com
Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Hengenix Biotech Inc
- Target Recruit Count
- 32
- Registration Number
- NCT04583228
- Locations
- 🇺🇸
Frontage Clinical Services, Inc., Secaucus, New Jersey, United States
Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Hengenix Biotech Inc
- Registration Number
- NCT04561076
© Copyright 2025. All Rights Reserved by MedPath